Clinical Trials Browser

Phase 2 × patritumab deruxtecan × Clear all

NCT05865990 2026-03-12

TUXEDO-3

Phase 2 Active not recruiting

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms

NCT06731907 2026-02-18

MK-3475-01G

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04619004 2026-01-23

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

277 enrolled 16 charts

Non-Small Cell Lung Cancer Metastatic

NCT04965766 2025-12-23

ICARUS BREAST

Phase 2 Recruiting

Breast Neoplasms

NCT04699630 2025-12-22

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06383884 2025-12-15

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT05620914 2025-06-15

PARAMETer

Phase 2 Withdrawn

Brain Neoplasms

NCT04479436 2025-05-18

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Phase 2 Terminated

40 enrolled 26 charts

Gastrointestinal

Colorectal Neoplasms

NCT05569811 2023-09-21

VALENTINE

Phase 2 Active not recruiting

Breast Neoplasms